



■ TEL. : 022 - 6825 2525  
■ FAX : 022 - 2405 7708  
■ E-Mail : info@naxparlab.com  
■ Visit us at: www.naxparlab.com  
■ CIN No. : L36912MH1982PLC027925

# Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX,  
SION-CHUNABHATTI, MUMBAI - 400 022. INDIA

**Date: 10/08/2022**

To,  
Department of Corporate Service (DCS-CRD),  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400001.

**Sub: Submission of Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30<sup>th</sup> June, 2022 in pursuance of Regulation 33 of Listing Obligation and Disclosure Requirement, 2015.**

**Ref: Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations) read with SEBI Circular CIR / CFD / CMD / 4 / 2015 dated September 09, 2015**

**Ref.: Parnax Lab Limited, Script Code- 506128**

Dear Sir,

Kindly find enclosed herewith the following:

1. A Copy of Standalone & Consolidated Un-Audited Financial Results of the Company for the quarter and three months ended 30<sup>th</sup> June, 2022, along with Limited Review Report thereon, pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2015.

**The aforesaid information and Financial Results are being made available on the Company's website at [www.naxparlab.com](http://www.naxparlab.com)**

Kindly take on your record and acknowledge receipt of the same.

Thanking You,

Yours faithfully,

**For PARNAX LAB LIMITED**

**PREET KUKREJA**  
**COMPANY SECRETARY & COMPLIANCE OFFICER**

**Encl: As above**





**C. N. PATEL & CO.**  
Chartered Accountants

Plot No. 12, Aradhana, State Bank Colony,  
Opp. Tidke Vidyalaya, Katol Road,  
Nagpur - 440013.  
Tel. No. +91 712 2584800, 9607844800  
Email ID : info@cnpca.in  
cnpca@rediffmail.com

To  
**The Board of Directors,**  
**Parnax Lab Limited,**  
114, Building No. 8,  
Jogani Industrial Complex,  
Chunabhatti, Mumbai – 400 022

1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Parnax Lab Limited** (“the company”) for the quarter ended June 30, 2022 together with the relevant notes thereon (“the Statement”). The Statement being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. The Statement is the responsibility of the company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principle laid down in Indian Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review in accordance with the standards on Review Engagement (SRE) 2410 ‘Review on Interim Financial Information Performed by the Independent Auditor of the Entity’, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For C. N. Patel & Co.  
Chartered Accountants  
Firm’s Registration No. : 112552W

CA Manish Mandhana  
Partner  
M. No. : 112026  
Place : Mumbai



Dated : 10<sup>th</sup> August, 2022  
UDIN : 22112026AOTOPU7582

Branch: 201 Metro Avenue, Pereira Hill Road, Off Andheri Kurla Road, Near WEH Metro Station, Mumbai - 400 099



**PARNAX LAB LIMITED**

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.  
Tel : 022 - 68252525, Fax : 2405 7708, Email : compliance@naxparlab.com, Website : www.naxparlab.com  
CIN:-L36912MH1982PLC027925

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2022**

(Rs. in Lakhs)

S. No.	Particulars	Quarter Ended			Year Ended
		30.06.2022 (Unaudited)	31.03.2022 (Audited)	30.06.2021 (Unaudited)	31.03.2022 (Audited)
I	Revenue from Operations	311.31	262.59	174.33	714.99
II	Other Income	7.84	6.65	2.75	16.16
III	<b>Total Revenue (I+II)</b>	<b>319.15</b>	<b>269.24</b>	<b>177.08</b>	<b>731.15</b>
IV	<b>Expenses</b>				
	a) Cost of Material Consumed	52.59	19.95	38.00	190.32
	b) Purchase of Stock in trade	118.28	67.14	55.24	148.28
	c) Changes in inventories of finished goods, Work in progress and stock in trade	-	-	-	-
	d) Employee benefits expenses	13.71	10.65	9.38	51.78
	e) Finance Costs	10.57	16.88	18.12	70.54
	f) Depreciation and amortisation expenses	1.11	1.39	1.02	4.47
	g) Other expenses	67.60	86.19	26.78	187.78
	<b>Total Expenses (IV)</b>	<b>263.87</b>	<b>202.20</b>	<b>148.54</b>	<b>653.17</b>
V	<b>Profit/(loss) before exceptional items and tax (III-IV)</b>	<b>55.28</b>	<b>67.04</b>	<b>28.54</b>	<b>77.98</b>
VI	Exceptional Items	-	-	-	-
VII	<b>Profit/(loss) Before Tax (V-VI)</b>	<b>55.28</b>	<b>67.04</b>	<b>28.54</b>	<b>77.98</b>
VIII	Tax expense	14.26	23.83	-	23.83
IX	<b>Profit/ (Loss) for the period (VII-VIII)</b>	<b>41.02</b>	<b>43.21</b>	<b>28.54</b>	<b>54.15</b>
X	<b>Other Comprehensive Income</b>				
	A. (i) Items that will not be reclassified to profit or loss	-	(2.86)	-	(2.86)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	0.72	-	0.72
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XI	<b>Total Other Comprehensive Income for the period</b>	<b>-</b>	<b>(2.14)</b>	<b>-</b>	<b>(2.14)</b>
XII	<b>Total Comprehensive Income comprising profit and other comprehensive income for the period (VIII+IX)</b>	<b>41.02</b>	<b>41.07</b>	<b>28.54</b>	<b>52.01</b>
XIII	<b>Paid-up equity share capital (Face Value of the share Rs. 10 )</b>	<b>981.49</b>	<b>851.20</b>	<b>850.49</b>	<b>851.20</b>
XIV	<b>Earning per equity share (Not Annualised)</b>				
	(1) Basic	0.42	0.51	0.34	0.64
	(2) Diluted	0.42	0.51	0.34	0.64

**Notes-**

- The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 10, 2022.
- The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter ended June 30, 2022
- EPS for quarter ended is on non annualised basis.
- The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
- Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

**By Order of the Board  
For Parnax Lab Limited**



Place : Mumbai  
Date : 10-08-2022

  
**Prakash M Shah  
Director & CEO  
DIN NO: 00440980**



**C. N. PATEL & CO.**  
Chartered Accountants

Plot No. 12, Aradhana, State Bank Colony,  
Opp. Tidke Vidyalaya, Katol Road,  
Nagpur - 440013.  
Tel. No. +91 712 2584800, 9607844800  
Email ID : info@cnpca.in  
cnpca@rediffmail.com

To  
**The Board of Directors,**  
**Parnax Lab Limited,**  
114, Building No. 8, Jogani Industrial Complex,  
Chunabhatti, Mumbai – 400 022

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Parnax Lab Limited** (“the Parent”) and **Naxpar Pharma Private Limited** (“the Subsidiary”) (the Parent and its subsidiary together referred to as “the Group”) for the quarter ended June 30, 2022 together with the relevant notes thereon (“the Statement”). The Statement submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. The Statement is the responsibility of the Parent’s management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principle laid down in Indian Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the standards on Review Engagement (SRE) 2410 ‘Review on Interim Financial Information Performed by the Independent Auditor of the Entity’, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Parent’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities

Parnax Lab Limited	Holding Company
Naxpar Pharma Private Limited	Subsidiary

5. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Branch: 201 Metro Avenue, Pereira Hill Road, Off Andheri Kurla Road, Near WEH Metro Station, Mumbai - 400 099








**C. N. PATEL & CO.**  
Chartered Accountants

Plot No. 12, Aradhana, State Bank Colony,  
Opp. Tidke Vidyalaya, Katol Road,  
Nagpur - 440013.  
Tel. No. +91 712 2584800, 9607844800  
Email ID : info@cnpca.in  
cnpca@rediffmail.com

6. The accompanying Statement includes the unaudited interim financial results and other unaudited financial information in respect of one subsidiary, whose unaudited interim financial results include total revenues of Rs. 3,422.85 lakhs for the quarter ended June 30, 2022, total net profit of Rs. 152.22 lakhs for the quarter ended June 30, 2022, total comprehensive income of Rs. Nil for the quarter ended June 30, 2022, as considered in the Statement which has been reviewed by its independent auditor. The independent auditor review reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiary is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement in respect of matters stated above in paragraph 6 above, is not modified with respect to our reliance on the work done and the reports of the other auditors.

**For C. N. Patel & Co.**  
**Chartered Accountants**  
**Firm's Registration No.: 112552W**

  
**CA Manish Mandhana**  
**Partner**  
**M. No.: 112026**  
**Place : Mumbai**



**Dated : 10<sup>th</sup> August, 2022**  
**UDIN : 22112026AOTPUS6978**

**PARNAX LAB LIMITED**  
 GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.  
 Tel : 022 - 68252525, Fax : 2405 7708, Email : compliance@naxparlab.com, Website : www.naxparlab.com  
 CIN:-L36912MH1982PLC027925

**STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2022**

S. No.	Particulars	(Rs. in Lakhs)			
		Quarter Ended		Year Ended	
		30.06.2022 (Unaudited)	31.03.2022 (Audited)	30.06.2021 (Unaudited)	31.03.2022 (Audited)
I	Revenue from Operations	3,673.93	4,791.18	2,869.43	16,303.17
II	Other Income	12.25	20.68	3.53	32.97
III	<b>Total Revenue (I+II)</b>	<b>3,686.18</b>	<b>4,811.86</b>	<b>2,872.96</b>	<b>16,336.14</b>
IV	Expenses				
	a) Cost of Material Consumed	1,779.40	2,826.83	1,555.58	9,113.02
	b) Purchase of Stock in trade	58.48	12.33	58.12	17.11
	c) Changes in inventories of finished goods, Work in progress and stock in trade	(23.43)	(138.25)	(133.88)	(165.78)
	d) Employee benefits expenses	466.52	437.84	377.70	1,742.98
	e) Finance Cost	126.23	136.82	117.22	523.03
	f) Depreciation and amortisation expenses	165.62	199.74	125.52	586.55
	g) Other expenses	861.82	951.49	675.11	3,292.81
	<b>Total Expenses (IV)</b>	<b>3,434.63</b>	<b>4,426.80</b>	<b>2,775.37</b>	<b>15,109.72</b>
V	Profit/(loss) before exceptional items and tax (III-IV)	251.55	385.06	97.59	1,226.42
VI	Exceptional Items	-	-	-	-
VII	<b>Profit/(loss) Before Tax (V-VI)</b>	<b>251.55</b>	<b>385.06</b>	<b>97.59</b>	<b>1,226.42</b>
VIII	Tax expense	58.31	400.60	-	400.60
IX	<b>Profit/ (Loss) After Tax for the period (VII-VIII)</b>	<b>193.24</b>	<b>(15.54)</b>	<b>97.59</b>	<b>825.82</b>
X	Other Comprehensive Income				
	A. (i) Items that will not be reclassified to profit or loss	-	(15.93)	-	(15.93)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	4.36	-	4.36
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XI	<b>Total Other Comprehensive Income for the period</b>	<b>-</b>	<b>(11.57)</b>	<b>-</b>	<b>(11.57)</b>
XII	<b>Total Comprehensive Income comprising profit and other comprehensive income for the period (IX + XIII)</b>	<b>193.24</b>	<b>(27.11)</b>	<b>97.59</b>	<b>814.25</b>
XIII	<b>Total profit/(loss) for the year attributable to:</b>				
	- Owners of the Company	192.94	(15.21)	97.45	824.28
	- Non-controlling interests	0.30	(0.33)	0.14	1.54
XIV	<b>Other Comprehensive income attributable to :</b>				
	- Owners of the Company	-	(11.55)	-	(11.55)
	- Non-controlling interests	-	(0.02)	-	(0.02)
XV	<b>Total Comprehensive income attributable to:</b>				
	- Owners of the Company	192.94	(26.76)	97.45	812.73
	- Non-controlling interests	0.30	(0.33)	0.14	1.52
XVI	<b>Paid-up equity share capital (Face Value of the share Rs. 10 )</b>	<b>981.49</b>	<b>981.49</b>	<b>850.49</b>	<b>851.20</b>
XVII	<b>Earning per equity share (Not Annualised)</b>				
	(1) Basic	1.97	(0.18)	1.15	9.70
	(2) Diluted	1.97	(0.18)	1.15	9.70

**Notes-**

- 1 The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.
- 2 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 10, 2022.
- 3 The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter ended June 30, 2022.
- 4 EPS for quarter ended is on non annualised basis.
- 5 The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
- 6 Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

By Order of the Board  
For Parnax Lab Limited



Place : Mumbai  
Date : 10-08-2022

Prakash M Shah  
Whole Time Director & CEO  
DIN NO: 00440980